Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Oppenheimer Keeps Their Buy Rating on Exact Sciences (EXAS)
01:13pm, Thursday, 19'th Mar 2020
Oppenheimer analyst
Kevin DeGeeter
maintained a
Buy
rating on Exact Sciences (
EXAS
–
Research Report
) today. The company’s shares closed last Monday at $37.90, close to its 52-week low of $35.25
RubrYc Therapeutics Appoints Ramesh Baliga, Ph.D. as Chief Science Officer
07:37pm, Wednesday, 18'th Mar 2020
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the app
Vericel (VCEL) Gets a Buy Rating from Oppenheimer
01:52pm, Tuesday, 17'th Mar 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vericel (VCEL). The company's shares closed last Monday at $10.84,
Vericel (VCEL) Gets a Buy Rating from Oppenheimer
01:52pm, Tuesday, 17'th Mar 2020
In a report released today,
Kevin DeGeeter
from Oppenheimer maintained a
Buy
rating on Vericel (
VCEL
–
Research Report
). The company’s shares closed last Monday at $10.84, close to its 52-week l
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
Edited Transcript of ASC.J earnings conference call or presentation 11-Mar-20 8:00am GMT
08:49pm, Thursday, 12'th Mar 2020
Half Year 2020 Ascendis Health Ltd Earnings Call
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
06:34pm, Thursday, 12'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA) yesterday and set a price target of $32.00. The company's shares closed last
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA – Research Report) yesterday and set a price target
Comparing Horiba (OTCMKTS:HRIBF) & Pressure Biosciences (OTCMKTS:PBIO)
05:28am, Monday, 09'th Mar 2020
Pressure Biosciences (OTCMKTS:PBIO) and Horiba (OTCMKTS:HRIBF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends
Becton Dickinson (BDX) Down 5.2% Since Last Earnings Report: Can It Rebound?
04:31pm, Saturday, 07'th Mar 2020
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
05:12am, Friday, 06'th Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR) today and set a price target of $20.00. The company's shares
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
05:12am, Friday, 06'th Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR – Research Report) today and set a
Amicus (FOLD) Receives a Rating Update from a Top Analyst
05:10am, Thursday, 05'th Mar 2020
In a report released today, Gbola Amusa from Chardan Capital reiterated a Hold rating on Amicus (FOLD), with a price target of $12.50. The company's
uniQure (QURE) Receives a Rating Update from a Top Analyst
03:26pm, Tuesday, 03'rd Mar 2020
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE) today and set a price target of $105.00. The company's shares closed last
